Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 5/20 | 0.40 |
| ▸ | IL2 | P60568 | 4/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019760 | 0.95 | IL2 (0.38) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL987243 | 0.88 | IL2 (0.43) | IL2TNFSTIM1ORAI1CHRNA7 | |
| SCHEMBL1782420 | 0.87 | IL2 (0.41) | IL2TNFSTIM1ORAI1CHRNA7 | |
| SCHEMBL5019598 | 0.83 | IL2 (0.40) | IL2TNFSTIM1ORAI1CHRNA7 | |
| SCHEMBL5019662 | 0.83 | IL2 (0.40) | CRACR2AIL2STIM1ORAI1NPC1 | |
| SCHEMBL1781986 | 0.83 | IL2 (0.46) | IL2NPC1RAB9AJAK1JAK2 | |
| SCHEMBL5019639 | 0.82 | IL2 (0.40) | IL2TNFSTIM1ORAI1CHRNA7 | |
| SCHEMBL5019740 | 0.81 | GAA (0.42) | IL2TNFSTIM1ORAI1KMT2A | |
| SCHEMBL5019607 | 0.79 | STIM1 (0.42) | CRACR2AIL2STIM1ORAI1NPC1 | |
| SCHEMBL5019638 | 0.78 | KMT2A (0.41) | CRACR2ACHRNA7KCNH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130289071-A1 | TETRAZOLYL-TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| WO-2010039236-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, CXCL8 | CRACR2A 2825/4885IL2 5/4885TNF 152/4885 |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | CRACR2A 3078/4885IL2 11/4885TNF 30/4885 |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | CRACR2A 3078/4885IL2 11/4885TNF 30/4885 |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | CRACR2A 3078/4885IL2 11/4885TNF 30/4885 |
| US-20130289071-A1 | TETRAZOLYL-TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, IL5, TPMT | CRACR2A 3705/4885IL2 5/4885TNF 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.